Seitz, Michael (2015). [Polymyalgia rheumatica: What is the current status?]. Zeitschrift für Rheumatologie, 74(6), pp. 507-510. Springer-Medizin-Verlag 10.1007/s00393-014-1548-z
|
Text
art%3A10.1007%2Fs00393-014-1548-z.pdf - Published Version Available under License Publisher holds Copyright. Download (287kB) | Preview |
The diagnosis of polymyalgia rheumatica (PMR) is based on the typical clinical symptoms and elevated inflammatory markers in blood; however, both are unspecific and the differential diagnosis of the disease still represents a challenge for clinicians. The new consensus classification criteria of the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) established in 2012 have a high sensitivity (92.6 %) and specificity (91.2 %) and therefore contribute to improved diagnostics. Glucocorticoids are still the standard treatment with methotrexate and as an alternative and possibly anti-interleukin (anti-IL) 6 therapy in the future.
Item Type: |
Journal Article (Review Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology |
UniBE Contributor: |
Seitz, Michael |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0340-1855 |
Publisher: |
Springer-Medizin-Verlag |
Language: |
German |
Submitter: |
Stefan Kuchen |
Date Deposited: |
14 Apr 2016 09:16 |
Last Modified: |
05 Dec 2022 14:55 |
Publisher DOI: |
10.1007/s00393-014-1548-z |
PubMed ID: |
26169748 |
Uncontrolled Keywords: |
Classification, Joint ultrasonography, Differential diagnoses, Glucocorticoids, Methotrexate |
BORIS DOI: |
10.7892/boris.80955 |
URI: |
https://boris.unibe.ch/id/eprint/80955 |
Actions (login required)
 |
Edit item |